http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109836502-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 |
| filingDate | 2018-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109836502-B |
| titleOfInvention | Bispecific antibody and application thereof |
| abstract | The invention discloses a bispecific antibody, which is obtained by coupling Fab structural domains of two antibodies with a first connecting arm and a second connecting arm respectively, and then carrying out azide-alkyne cycloaddition reaction on an azide linker and an alkyne linker between the two connecting arms. Compared with the traditional preparation method of the bispecific antibody, the preparation method of the bispecific antibody has the advantages of high expression level, high coupling efficiency and high assembly accuracy, the bispecific antibody in the form has higher affinity and specificity, can effectively activate lymphocytes in vitro and in vivo and generate specific killing on CD20 positive tumor cells, is easier to penetrate solid tumors due to lack of Fc sections of the antibody, and has higher specificity by avoiding the toxic and side effects of nonspecific killing caused by Fc. |
| priorityDate | 2018-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 420.